Trial · NCT07320326
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
NCT07320326, Not yet recruiting, Peking University People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab. Trials, record NCT07320326. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07320326
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
- NCT number
- NCT07320326
- Status
- Not yet recruiting
- Enrollment
- 159 participants, estimated
- Lead sponsor
- Peking University People's Hospital
- Conditions
- TCE-RRMM
- Interventions
- Elranatamab
- First posted
- 2026-01-06
- Last updated
- 2026-01-06
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ORR | At the time from the date of first dose until the first documentation of PD, death or start of new anticancer therapy, whichever occurs first , assessed up to 27 months. | Overall Response Rate (ORR):(including PR, VGPR, CR, and sCR) |
| Secondary | PFS | As the time from the date of first dose until PD per IMWG criteria or death due to any cause, whichever occurs first, assessed up to 27 months. | Progression-freesurvival |
| Secondary | OS | As the time from the date of first dose until death due to any cause, assessed up to 27 months. | Overall survival |
| Secondary | DOR | As the time from the first documentation of objective response that is subsequently confirmed, until PD per IMWG criteria, or death due to any cause, whichever occurs first, assessed up to 27 months. | Duration of response |
| Secondary | MRD negativity rate | The proportion of participants in the analysis population with negative MRD per IMWG criteria by BMA at any time after first dose, assessed up to 27 months. | Minimal Residual Disease negativity rate |
| Secondary | TTR | For participants with an objective response per IMWG criteria, as the time from the date of first dose to the first documentation of objective response that is subsequently confirmed, assessed up to 27 months. | Time to response |
| Secondary | PRO: EORTC QLQ-C30、EORTC QLQ-MY20 and EQ-5D-5L will be used in this study | From the screening visit to the last follow up visit, assessed up to 27 months. | To evaluate the patient-reported outcomes of Elranatamab-treated TCE-RRMM patients in China using the following patient-reported outcome (PRO) instruments: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ-C30) European Organization for Research and Treatment of Cancer Multiple Myeloma Questionnaire (EORTC QLQ-MY20) The EuroQol 5-Dimension 5-level (EQ-5D-5L) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07320326
GET https://conductscience.org/api/trials/v1/NCT07320326/registered